Piramal Life Sciences CEO Somesh Sharma On Managing Risk And India's Potential For Discovering New Drugs: An Interview With PharmAsia News (Part 1 of 2)
This article was originally published in PharmAsia News
Executive Summary
Piramal Life Sciences CEO Somesh Sharma keeps a very low profile and does not speak much about his three decades of leading start-ups in the U.S., but his passion for research has fueled the determination of the Piramal Healthcare group to discover and develop a new molecular compound - which would be a first for India's pharma industry.
You may also be interested in...
India’s Piramal Ropes In Big Pharma Heavyhitters To Support Late-Stage R&D
MUMBAI - A progressively maturing pipeline of innovative compounds has led Piramal Healthcare Ltd. to begin adding leadership positions to its core research team. Piramal is believed to be drawing senior-level executives from established global companies in functions like drug discovery, development, international regulatory affairs and marketing strategies to ramp up expertise in late-stage processes
India’s Piramal Ropes In Big Pharma Heavyhitters To Support Late-Stage R&D
MUMBAI - A progressively maturing pipeline of innovative compounds has led Piramal Healthcare Ltd. to begin adding leadership positions to its core research team. Piramal is believed to be drawing senior-level executives from established global companies in functions like drug discovery, development, international regulatory affairs and marketing strategies to ramp up expertise in late-stage processes
Piramal Life Sciences CEO Somesh Sharma On Managing Risk And India's Potential For Discovering New Drugs: An Interview With PharmAsia News (Part 2 of 2)
Piramal Life Sciences CEO Somesh Sharma keeps a very low profile and does not speak much about his three decades of leading start-ups in the U.S., but his passion for research has fueled the determination of the Piramal Healthcare group to discover and develop a new molecular compound - which would be a first for India's pharma industry.